Product Description
Overall, the global percutaneous transluminal angioplasty balloon market was valued at $539 million in 2023. This is expected to increase over the forecast period at a CAGR of 2.7% to reach almost $652 million.
Throughout this medical market research, we analyzed over 24 percutaneous transluminal angioplasty balloon companies globally and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.
DATA TYPES INCLUDED
- Procedure Numbers, Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2029, and Historical Data to 2019
- Market Drivers & Limiters for Each Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- COVID19 Impact
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
Global Percutaneous Transluminal Angioplasty Balloon Market Insights
A notable development in the worldwide PTA balloon market involves the growing utilization of drug-coated balloons (DCBs) in addressing peripheral arterial disease (PAD). DCBs are designed with a specialized coating that dispenses an anti-proliferative medication upon balloon inflation, specifically targeting the vessel wall to diminish the likelihood of restenosis. This shift signifies a transition towards less invasive and precisely targeted techniques in vascular interventions, promising enhanced results for individuals dealing with PAD and potentially decreasing the necessity for supplementary procedures.
Global Percutaneous Transluminal Angioplasty Balloon Market Share Insights
Boston Scientific showcases its prominent offerings in both the standard and specialty balloon segments. Within the standard realm, the Mustang™ and Coyote™ balloon catheters stand out, while in the emerging specialty PTA balloon segment, the Flextome™ Cutting Balloon™ Dilatation Device holds a strong position. The acquisition of Cryterion Medical in 2018 further fortified the company’s portfolio with a single-shot cryoablation platform. Recently, in April 2023, Boston Scientific obtained CE mark approval for its POLARx FIT cryoballoon catheter, a significant advancement for arterial fibrillation (AF) ablation.
The popularity of the Conquest™ high-pressure balloon endures due to its impressive performance among physicians. Intellectual property plays a crucial role in this market, with Becton Dickinson (BD) holding essential patents for high-pressure balloon technology. Competitors often maneuver around patent constraints by developing balloons with thicker walls and a higher profile, potentially compromising desired low-profile attributes. BD’s adaptable Atlas® device, renowned for its low profile and high burst pressure, remains versatile across various procedure types. Complementing this offering, Dorado® and Conquest® feature higher rated burst pressures (RBPs) of 24 and 30 atmospheres, respectively.
Medtronic maintains its market dominance through notable contributions from products like the Admiral Xtreme™, Evercross™, and Chocolate™ balloon catheters. The unique Chocolate™ balloon, incorporating a nitinol cage for controlled dilatation, stands out by preventing the propagation of dissections by creating smaller ones. Additionally, Medtronic’s RapidCross™, Reef™, and Amphirion™ Deep balloons further enrich its product portfolio, spanning across various categories within this segment.
Market Segmentation Summary
- Standard PTA Balloon Catheters
- High-Pressure PTA Balloon Catheters
- Large PTA Balloon Catheters
- Small PTA Balloon Catheters
- Specialty PTA Balloon Catheters
Global Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.) Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam) Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2023 |
| Forecast | 2024-2030 |
| Historical Data | 2020-2023 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | COVID19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
